Biology subjects

Walker, V. M.

Publications and source records attributed to Walker, V. M..

6 recordsLinked to original sources

bioRxiv2026

Identification of Dynamic Genetic Influences on DNA Methylation from Birth to Adulthood

Whether and how genetic regulation of DNA methylation (DNAm) change across the lifespan remains unclear. Here, we map age-dependent methylation quantitative trait loci (longitudinal mQTLs) using linear mixed models applied to repeated blood DNAm measures from birth, childhood, adolescence and adulthood in the Avon Longitudinal Study of Parents and Children. We identify 2,210 longitudinal mQTLs (2,393 SNP-CpG pairs; 7.3% trans) and observe consistent genotype-by-age effects in two independent cohorts of diverse ancestries (Pearsons r = 0.85 in the Generation R Study; r = 0.56 in the Drakenstein Child Health Study). Longitudinal mQTLs show increasing effects with age at half of loci and associations with multiple phenotypes. CpGs with longitudinal mQTLs are more heritable and enriched in regulatory elements and pathways related to multicellular organism development and cell adhesion. These results chart dynamic genetic influences on the human methylome and provide a novel perspective on epigenetic regulation.

genomics↗

bioRxiv2021

Genetic effect modification of cis-acting C-reactive protein variants in cardiometabolic disease status

Mendelian randomization (MR) studies carried out among patients with a particular health condition should establish the genetic instrument influences the exposure in that subgroup, however this is normally investigated in the general population. Here, we investigated whether the genetic associations of four cis-acting C-reactive protein (CRP) variants differed between participants with and without three cardiometabolic conditions: obesity, type 2 diabetes, and cardiovascular disease. Associations of cis-genetic variants with CRP differed between obese and non-obese individuals. A multivariable analysis suggested strong independent associations of the gene-by-body mass index (BMI) interaction on CRP (P<1.18x10-8 for the CRP variants). Applying MR, we observed strong causal effect of BMI on CRP (P=2.14x10-65). In summary, our study indicates that genetic associations with CRP differ across disease sub-groups, with evidence to suggest that BMI is an effect modifier. MR studies of disease progression should report on the genetic instrument-exposure association in the disease subgroup under investigation.

genetics↗

bioRxiv2019

Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases

The human proteome is a major source of therapeutic targets. Recent genetic association analyses of the plasma proteome enable systematic evaluation of the causal consequences of variation in plasma protein levels. Here, we estimated the effects of 1002 proteins on 225 phenotypes using two-sample Mendelian randomization (MR) and colocalization. Of 413 associations supported by evidence from MR, 130 (31.5%) were not supported by results of colocalization analyses, suggesting that genetic confounding due to linkage disequilibrium (LD) is widespread in naive phenome-wide association studies of proteins. Combining MR and colocalization evidence in cis-only analyses, we identified 111 putatively causal effects between 65 proteins and 52 disease-related phenotypes (www.epigraphdb.org/pqtl/). Evaluation of data from historic drug development programmes showed that target-indication pairs with MR and colocalization support were more likely to be approved, evidencing the value of our approach in identifying and prioritising potential therapeutic targets.

genetics↗

bioRxiv2018

Repurposing antihypertensive drugs for the prevention of Alzheimer’s disease: a Mendelian Randomization study

BackgroundEvidence concerning the potential repurposing of antihypertensives for Alzheimers disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood pressure (SBP), via different antihypertensive drug classes, on Alzheimers disease.\n\nMethodsWe used summary statistics from genome wide association studies of SBP (from UK Biobank) and Alzheimers disease (from the International Genomics of Alzheimers Project) in a two-sample Mendelian randomization analysis. We identified single nucleotide polymorphisms (SNPs) that mimic the action of antihypertensive targets and estimated the effect of lowering SBP, via antihypertensive drug classes, on Alzheimers disease. We also report the effect of lowering SBP on Alzheimers disease by combining all drug targets and without consideration of the associated drugs.\n\nResultsThere was limited evidence that lowering SBP, via antihypertensive drug classes, affected Alzheimers disease risk. For example, calcium channel blockers had an odds ratio (OR) per 10mmHg lower SBP of 1.53 (95% confidence interval (CI): 0.94 to 2.49; p=0.09; SNPs=17). We also found limited evidence for an effect of lowering SBP on Alzheimers disease when combining all drug targets (OR per 10mmHg lower SBP: 1.14; 95%CI: 0.83 to 1.56; p=0.41; SNPs=59) and without consideration of the associated drug targets (OR per 10mmHg lower SBP: 1.04; 95%CI: 0.95 to 1.13; p=0.45; SNPs=153).\n\nConclusionsLowering SBP itself is unlikely to affect risk of developing Alzheimers disease. Consequently, if specific antihypertensive drug classes do affect risk of Alzheimers disease, they are unlikely to do so via SBP.\n\nKEY MESSAGESO_LIThis is the first study to use Mendelian randomization to estimate the effects of the twelve most common antihypertensive drug classes on Alzheimers disease.\nC_LIO_LILowering systolic blood pressure itself is unlikely to affect risk of developing Alzheimers disease.\nC_LIO_LIIf specific antihypertensive drug classes do affect Alzheimers disease risk, they are unlikely to do so via systolic blood pressure.\nC_LI

genetics↗

bioRxiv2017

Mendelian randomization: a novel approach for the prediction of adverse drug events and drugrepurposing opportunities

Identification of unintended drug effects, specifically drug repurposing opportunities and adverse drug events, maximizes the benefit of a drug and protects the health of patients. However, current observational research methods are subject to several biases. These include confounding by indication, reverse causality, and missing data. We propose that Mendelian randomization (MR) offers a novel approach for the prediction of unintended drug effects. In particular, we advocate the synthesis of evidence from this method and other approaches, in the spirit of triangulation, to improve causal inferences concerning drug effects. MR overcomes some of the limitations associated with the existing methods in this field. Furthermore, it can be applied either pre- or post-approval of the drug and could therefore prevent the potentially harmful exposure of patients in clinical trials and beyond. The potential of MR as a pharmacovigilance and drug repurposing tool is yet to be realized and could both help prevent adverse drug events and identify novel indications for existing drugs in the future.

pharmacology and toxicology↗

bioRxiv2016

Power calculator for instrumental variable analysis in pharmacoepidemiology

BackgroundInstrumental variable analysis, for example with physicians prescribing preferences as an instrument for medications issued in primary care, is an increasingly popular method in the field of pharmacoepidemiology. Existing power calculators for studies using instrumental variable analysis, such as Mendelian randomisation power calculators, do not allow for the structure of research questions in this field. This is because the analysis in pharmacoepidemiology will typically have stronger instruments and detect larger causal effects than in other fields. Consequently, there is a need for dedicated power calculators for pharmacoepidemiological research.\n\nMethods and resultsThe formula for calculating the power of a study using instrumental variable analysis in the context of pharmacoepidemiology is derived before being validated by a simulation study. The formula is applicable for studies using a single binary instrument to analyse the causal effect of a binary exposure on a continuous outcome. A web application is provided for the implementation of the formula by others.\n\nConclusionsThe statistical power of instrumental variable analysis in pharmacoepidemiological studies to detect a clinically meaningful treatment effect is an important consideration. Research questions in this field have distinct structures that must be accounted for when calculating power.\n\nFUNDING STATEMENTThis work was supported by the Perros Trust and the Integrative Epidemiology Unit. The Integrative Epidemiology Unit is supported by the Medical Research Council and the University of Bristol [grant number MC_UU_12013/9]. Stephen Burgess is supported by a post-doctoral fellowship from the Wellcome Trust [100114].\n\nKey MessagesO_LIResearch questions using instrumental variable analysis in pharmacoepidemiology have distinct structures that have previously not been catered for by instrumental variable analysis power calculators.\nC_LIO_LIPower can be calculated for studies using a single binary instrument to analyse the causal effect of a binary exposure on a continuous outcome in the context of pharmacoepidemiology using the presented formula and online power calculator.\nC_LIO_LIThe use of this power calculator will allow investigators to determine whether a pharmacoepidemiology study is likely to detect clinically meaningful treatment effects prior to the studys commencement.\nC_LI

epidemiology↗